COVID researchers are working at a fast pace to learn about infection, severity and the ability to avoid this type of vaccine. For the past week scientists in Botswana and South Africa have been warning the world of the spread of SARS-CoV-2 now known as Omicron. Researchers around the world are trying to understand the current threat - which has now been confirmed in more than 20 countries - worldwide. However, it may take weeks for scientists to draw a complete picture of the Omicron, as well as to understand its sharpness and size, as well as its ability to evade goals and cause recurrence. How fast is Omicron spreading?
Omicron Rapid Rise In Africa is of great concern to researchers, as it suggests that the exception could lead to an increase in the incidence of COVID-19 in some areas. On December 1, South Africa recorded 8,561 incidents, up from 3,402 reported on November 26 and a few hundred a day in mid-November, with significant growth taking place in the Gauteng province, home to Johannesburg.
Epidemiologists measure the magnitude of the epidemic using R, which is a measure of the number of new infections caused by each infection. At the end of November, the National Institute for Communicable Diseases (NICD) of South Africa in Johannesburg ruled that R was more than 2 in Gauteng. That growth was evident in the early days of the epidemic, Richard Lessells, an infectious disease specialist at the University of KwaZulu-Natal in Durban, South Africa, told a news conference last week.
University of R. at Leuven in Belgium, Based on the increase in COVID-19 cases and data tracking, Wenseleers estimated that Omicron could infect three to six times as many people as Delta, at one time. "That 's a huge advantage over the virus - but not for us," he adds.
Researchers will look at how Omicron has spread to other parts of South Africa and around the world to better study its transmission, says Christian Althaus, a dermatologist at the University of Bern, Switzerland. High vigilance in South Africa may cause researchers to overestimate Omicron's rapid growth. But if this pattern is repeated in other countries, it could be very strong evidence that Omicron has a transfer advantage, adds Althaus. "If this does not happen, for example in European countries, it means that things are more complex and more dependent on the immune system. So we have to wait."
Although genome sequencing is required to confirm Omicron conditions, some PCR tests may find a distinct marker that separates it from Delta. On the basis of this sign, there are early indications that cases, although very low in number, are on the rise in the United Kingdom. "That 's not what we want to see now and we suggest that Omicron may have a chance to transfer to the UK," Althaus said.
Can Omicron overcome resistance to vaccines or diseases?
The rapid growth of this species in South Africa shows that it has the potential to prevent disease. About a quarter of South Africa's population has been fully vaccinated, and it is possible that a large number of people were infected by SARS-CoV-2 in recent waves, Wenseleers said, looking at the high death toll since the epidemic began.
The success of Omicron in South Africa :
In this context, the success of Omicron in southern Africa may be due to its ability to infect COVID-19 survivors caused by Delta and other species, as well as those vaccinated. A December 2 preprint1 from NICD researchers found that recurrence of infections in South Africa is increasing as Omicron grows. "Unfortunately, this is a good place to develop a different immune-scape," Althaus said.
How the Virus Spreads : well in other areas may depend on factors such as vaccination and previous infection rates, says Aris Katzourakis, who is researching the spread of the virus at Oxford University, in the UK. “If you throw it in a crowd of people who are heavily vaccinated and stop using other methods to control it, it may end up there. What will be the goals against Omicron?
If Omicron is able to suppress a weakened immune system, it does not mean that the immune system caused by previous vaccines and infections will not provide a vaccine. Immune research suggests that a modest immune system can protect people from severe forms of COVID-19, says Miles Davenport, a orthopedic surgeon at the University of New South Wales in Sydney, Australia.
Some antibodies, especially T cells, may be less affected by Omicron mutations than antibody responses. South African researchers plan to measure the activity of T cells and other antibodies called natural immune cells, which could be important in protecting the heavy COVID-19, said Shabir Madhi, a vaccineologist at the University of the Witwatersrand.
Madhi, who led the study of the COVID-19 vaccine in South Africa, is also part of an effort to conduct epidemiological studies on the effectiveness of the Omicron vaccine. There are unexplained reports of successful infections involving all three vaccines given in South Africa - Johnson & Johnson, Pfizer-BioNTech and Oxford-AstraZeneca. But Madhi says researchers will want to measure Omicron's level of protection against vaccines, as well as past infections.
He suspects that the results will remind us of how the AstraZeneca - Oxford vaccine has acted against the Beta version, which is different from the antibodies that will be available in South Africa by the end of 2020. A study led by Madhi found that a vaccine was given. little or no protection. with moderate disease.
You must be logged in to post a comment.